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Abstract 
The urokinase-type lasminogen activator plays a central role in tissue remodeling by controlling the synthesis of the extracellular 
matrix-degrading plasmin. Urokinase xpression is transcriptionally regulated by a variety of cytokines including TNF-c~. The present 
study was undertaken to identify key transcription factor binding sites in the urokinase promoter necessary for the TNF-a-dependent 
induction of urokinase xpression. TNF-a treatment of a squamous cell carcinoma cell line, UM-SCC-1, which produces no detectable 
TNF-a, led to a dose-dependent i crease in urokinase secretion, thus reflecting a more abundant mRNA. Transient ransfections of 
UM-SCC-1 cells with a CAF reporter driven by 5' deletion fragments of the urokinase promoter indicated that a sequence spanning 
-2109 to - 1870, which contained binding sites for AP-1 and PEA3 was required for the stimulation by TNF-a. Mutation of an AP-I 
binding site at - 1967 and a PEA3 motif at - 1973 completely abrogated the inductive ffect of TNF-a on urokinase promoter activity. 
Mobility shift assays indicated the presence of a jun-containing factor(s) which bound specifically to the AP-1 sequence present in the 
urokinase promoter. The amount and/or activity of this factor(s) was greatly enhanced by TNF-a treatment. UM-SCC-1 ceils transiently 
transfected with a CAT reporter driven by 3 tandem AP-1 binding sites demonstrated increased CAT activity following TNF-a treatment. 
Thus, the induction of urokinase xpression by TNF-a is likely to involve the altered expression and/or activity of transcription factors 
which bind to the AP-1 and PEA3 target sequences in the urokinase promoter. 
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1. Introduction 
The urokinase-type plasminogen activator (u-PA) plays 
a central role in tissue remodeling in a number of physio- 
logical and pathological processes including tissue repair, 
pregnancy, angiogenesis and tumor cell invasion [1,2] by 
mediating the conversion of the inert zymogen plasmino- 
gen into the widely acting serine protease plasmin [3]. 
Plasmin in turn degrades everal extracellular matrix com- 
ponents including laminin and fibronectin [4] and there is 
some evidence that type IV collagenase may be activated 
by this serine protease [5]. 
Urokinase expression is modulated by a variety of 
growth factors/cytokines including TNF-a. [6-8]. TNF-a 
is a multifunctional M r 17 kDa cytokine produced primar- 
ily by activated macrophages usually in response to in- 
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flammatory products and invasive stimuli [9]. This cy- 
tokine was initially identified as a mediator of hemorrhagic 
necrosis of tumors and subsequently found to have a 
number of biological effects including modulation of 
growth and differentiation [10,11]. The gene for TNF-a 
encodes a prohormone that is first inserted into the cell 
membrane and subsequently cleaved to generate a soluble 
17 kDa polypeptide [11]. Trimeric TNF-a binds with 
equal affinity to two separate and ubiquitously expressed 
TNF-a receptors (p55 and p75) which are readily distin- 
guished by their divergent cytoplasmic tails [12]. The 
interaction of TNF-a with its receptor(s) leads to receptor 
clustering followed by the stimulation of one, or multiple, 
signal transduction pathways including protein kinase C, 
protein kinase A and sphingomyelin [9,13,14]. Although 
the increased production of urokinase by TNF-a has been 
ascribed to an increased rate of transcription of the plas- 
minogen activator gene, the mechanism by which the 
promoter is activated in trans has not been investigated. 
Consequently, we undertook a study to determine the 
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transcriptional requirements for augmented urokinase pro- 
moter activity in response to TNF-a. 
2. Materials and methods 
2.1. Materials 
Recombinant human TNF-a was obtained from Genen- 
tech, San Francisco, CA. The urokinase antibody (#389) 
used in Western blotting was from American Diagnostica, 
Greenwich, CT. The jun Ab (SC 44 X ) antibody, which 
cross-reacts with c-jun, jun B and jun D, was obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA). 
2.2. Cell culture 
UM-SCC-1 cells were propagated in McCoys 5A 
medium supplemented with 10% FBS. These cells do not 
produce any detectable TNF-t~ as determined by a bioas- 
say on L929 cells [15]. For the collection of conditioned 
medium, the cells were washed extensively and changed to 
serum-free medium (McCoys' 5A supplemented with 4 
/xg/ml transferrin, 5 /zg/ml insulin and 10 ng/ml EGF 
and 0.1 w/v  %BSA) containing TNF-a. 
2.3. Western blotting 
UM-SCC-1 cells were grown to 70% confluency in 
10% FBS and, after extensive washing with serum-free 
medium, changed to serum-free medium supplemented as
needed with TNF-t~. The cells were incubated for 24-36 h 
and the conditioned medium harvested and clarified. The 
amount of urokinase in the conditioned medium was deter- 
mined by Western blotting [16]. Briefly, conditioned 
medium from equal numbers of cells was denatured in the 
absence of reducing agent and electrophoresed in a 12.5% 
SDS-PAGE gel. The resolved proteins were transferred to 
a nitrocellulose filter. The filter was blocked with 3% BSA 
and incubated sequentially with a polyclonal antibody to 
urokinase #389 (American Diagnostica, Greenwich, CT) 
and a horse radish peroxidase conjugated anti-rabbit IgG. 
Immunoreactive bands were visualized by ECL as de- 
scribed by the manufacturer (Amersham, Arlington 
Heights, IL). 
2.4. Northern blotting 
UM-SCC-1 cells at 70% confluency, treated with TNF-a 
as described above, were extracted for total RNA with 5.0 
M guanidinium isothiocyanate. The RNA was purified on 
a cesium chloride cushion (5.7 M) by ultracentrifugation. 
Purified RNA was electrophoresed in a 1.5% formal- 
dehyde-agarose g l and transferred to Nytran R modified 
nylon by capillary action. The Northern blot was probed at 
42°C with a random-primed, [32p]-labeled 1.5 kb cDNA 
specific for the urokinase mRNA [17] and subsequently 
washed at 65°C using 0.5 X SSC in the presence of 1.0% 
SDS. Loading efficiencies were checked by reprobing the 
blot with a radioactive cDNA which hybridizes with the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
mRNA. 
2.5. Chloramphenicol acetyl transferase (CAT) assays 
The urokinase promoter CAT constructs used in the 
present study have been described elsewhere [18-20]. The 
AP-1 thymidine kinase CAT reporter used was described 
previously [21 ]. UM-SCC-1 cells, at 70% confluency, were 
co-transfected with urokinase promoter-CAT reporter con- 
structs and 5 /zg of an expression vector bearing the 
fl-galactosidase g ne. Briefly, DNA, in 1 ml of HBS (pH 
7.44) buffer (Hepes, 25 mM; MgC12, 1 /zM; CaCI2, 0.1 
/zM; NaC1, 0.1 M; KC1, 5 /xM; and Na2HPO4, 0.7/zM), 
was mixed with 50 /xg hexadimethrine bromide (Aldrich 
Chemicals, Wisconsin) and added to the cells in 10% FBS. 
After 5 h, the cells were shocked for 3 min with 33% 
DMSO and cultured for 12 h after which the transfected 
cells were treated with TNF-a. After an additional 36 h, 
the cells were harvested and lysed by repeated freeze-thaw 
cycles in a buffer containing 0.25 M Tris-C1 (pH 7.8). 
Transfection efficiencies were determined by assaying for 
fl-galactosidase activity. CAT activity was subsequently 
measured by incubating cell lysate (normalized for trans- 
fection efficiency) at 37°C for 8 h with 4/xM [14C]chlor- 
amphenicol and 1 mg/ml acetyl coenzyme A. After 3 h, 
the acetyl CoA in the reaction mixture was replenished. 
The mixture was extracted with ethyl acetate and acety- 
lated products ubjected to thin layer chromatography us- 
ing chloroform:methanol (95:5) as a mobile phase. The 
conversion of [14C]chloramphenicol was quantified with a 
603 Betascope. 
2.6. Mobility shift assays 
TNF-a-treated and untreated cells were collected by 
centrifugation, washed and suspended in a buffer contain- 
ing l0 mM Hepes (pH 7.9), 10 mM KC1, 0.1 mM EDTA, 
0.1 mM EGTA, 1 mM DT~ and 0.5 mM PMSF. After 15 
min on ice, the cells were vortexed in the presence of 0.6% 
Nonidet NP-40. The nuclear pellet was collected by cen- 
trifugation and extracted in a buffer containing 20 mM 
Hepes (pH 7.9), 0.4 M NaC1, 1 mM EDTA, lmM EGTA, 
1 mM DTT and l mM PMSF for 15 min at 4 ° C. 
UM-SCC-1 nuclear extract (8 /zg) from TNF-a-stimu- 
lated and unstimulated cells was preincubated at 4 ° C for 
30 min with, or without, 2 /zg of a jun antibody followed 
by an incubation at 4 ° C for 20 min in a buffer (25 mM 
Hepes buffer (pH 7.9), 0.5 mM EDTA, 0.5 mM D'IT, 0.05 
M NaC1 and 2.5% glycerol) containing 5 fmol (2. 104 
cpm) of a Klenow end-labelled (32p-ATP) 30-mer oligo- 
nucleotide spanning the AP-1 binding site at - 1967 of the 
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urokinase promoter. Parallel incubations included the wild 
type (TTCTTFGTCCAGGAGGAAATGAAGTCATCTG)  
and mutated (TTCTTTGTCCAGGAGGAAATccAGa-  
gATCTG) (lower case letters indicate the mutated nu- 
cleotides) AP-1 competitor sequence at a 100-fold excess. 
To reduce non-specific probe interactions, all incubations 
were carried out in the presence of 2.0 /xg of poly dI.dC. 
At the end of the incubation period, the reaction mixture 
was electrophoresed at 4 ° C in a 6% polyacrylamide gel 
using a 0.5 × TBE running buffer. 
3. Results 
3.1. TNF-a increases the amount of urokinase protein/ 
mRNA in UM-SCC-1 cells 
A dose-dependent increase in urokinase secretion was 
evident with UM-SCC-1 cells treated with TNF-a  (Fig. 
1A). This increase was not secondary to increased growth 
rate since we could find no evidence of augmented prolif- 
eration of UM-SCC-1 cells in the presence of TNF-oL. 
Northern blotting (Fig. 1B,C) indicated that the increased 
secretion of urokinase by TNF-a-stimulated UM-SCC-1 
cells was a consequence of a larger amount of steady-state 
mRNA encoding the plasminogen activator. 
3.2. Induction of urokinase promoter activity by TNF-a 
requires 2109 bp of 5' flanking sequence 
We undertook experiments to identify the region of the 
urokinase promoter equired for its stimulation by TNF-cr. 
UM-SCC-1 cells were transiently transfected with a CAT 
reporter driven by the full length (2345 bp) or 5' deletion 
fragments of the urokinase promoter. The transfected cells 
were subsequently treated with 250 ng /ml  of TNF-a  for 
48 h. After this time, the cells were harvested and assayed 
for CAT activity. TNF-a  treatment of UM-SCC-1 cells 
transiently transfected with the full length (2345 bp) uroki- 
nase promoter-CAT reporter increased [14C]chloramphe- 
nicol conversion from 17 to 37% (Fig. 2). A similar 
augmentation was observed using 2109 bp of the 5' flank- 
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Fig. 1. TNF-ot induces urokinase protein and mRNA levels. UM-SCC-1 cells at 70% confluency, were washed extensively and changed to serum-free 
medium supplemented with, or without, he indicated concentration f TNF-ot for 36 h. After this time, the conditioned medium was collected, clarified by 
centrifugation a d the cells counted. Aliquots of the conditioned medium, normalized for cell number, along with authentic urokinase standard (rSC-u-PA) 
was subjected to Western blotting using a polyclonal antibody (panel A). mRNA was extracted from a parallel flask treated in an identical manner and 
purified on a CsC1 cushion. The purified RNA was electrophoresed in a 1.5% forrnaldehyde-agarose gel and subsequently ransferred to a Nytran-modified 
nylon filter. The filter was probed with cDNAs specific for the urokinase and GAPDH transcripts (panel B). Radioactivity was quantified using a 603 
Betascope and the results are shown in panel C. The experiment was carried out twice. 
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Fig. 2. Stimulation of the urokinase promoter by TNF-a requires 2109 bp of 5' flanking sequence. UM-SCC-1 cells were transiently transfected with a 
DNA mixture of a CAT reporter (10/~g) driven by the indicated fragment of the urokinase promoter, 5/~g of a fl-galacotosidase expression vector and 50 
/~g of hexadimethrine bromide. After 5 h, the cells were shocked for 3 rain with 33% DMSO. The UM-SCC-1 cells were incubated for a further 12 h, after 
which the cells were treated with 250 ng/ml  of TNF-t~ for a period of 48 h. The cells were harvested, lysed by repeated freeze-thaw cycles and assayed 
for fl-galacotosidase activity. Aliquots, adjusted for transfection efficiency, were incubated at 37 ° C for 8 h with 4 gM [14C]chloramphenicol and 1 mg/ml  
acetyl coenzyme A. The mixture was subsequently extracted with ethyl acetate and the acetylated products ubjected to thin-layer chromatography using 
chloroform:methanol (95:5) as a mobile phase. The conversion of [14C]chloramphenicol (graph) was quantified using a 603 Betascope. The data are typical 
of more than 4 separate xperiments. 
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Fig. 3. Stimulation of urokinase promoter activity by TNF-a requires binding sites for AP-1 and PEA3. UM-SCC-1 cells were transiently transfected with 
a CAT reporter driven by the full-length (2345 bp) wild type urokinase promoter (wt) or the mutated promoter as described in the legend to Fig. 2. The 
ceils were subsequently treated with (+) ,  or without ( - ) ,  250 ng /ml  TNF-ot for 36 h. The cells were harvested, lysed and assayed for CAT activity 
following normalization of /3-galacotosidase activities. A schematic of the urokinase promoter spanning - 1973 to - 1885 is shown at the right with the 
blocked areas representing mutations. The data are representative of 4 separate xperiments. 
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ing sequence of the urokinase gene. In contrast, [14C]chlor- 
amphenicol conversions in UM-SCC-1 cells transiently 
transfected with the CAT reporter driven by 1870 bp of the 
urokinase promoter was not altered in response to TNF-c~. 
These data suggest hat the sequence residing between 
-2109 and - 1870 is critical for the stimulation of uroki- 
nase promoter activity by TNF-a. The modest changes in 
CAT activity seen in TNF-a-stimulated cells, when com- 
pared with those seen by Western and Northern blotting 
(Fig. 1), may reflect two factors. First, there is a basal 
activity of the urokinase promoter in the unstimulated 
UM-SCC-1 cells utilized in the present study. Secondly, a
limited supply of transactivators in the TNF-c~-treated cells 
may be insufficient to stimulate the multiple copies of the 
exogenous urokinase promoter-CAT reporter introduced 
into the cells by transfection. Notwithstanding these possi- 
bilities, these data suggest hat the elevation of urokinase 
mRNA and protein by TNF-a in UM-SCC-1 cells reflects, 
at least in part, increased urokinase promoter activity and 
requires a region of the promoter residing between -2109 
and - 1870. 
3.3. Binding sites for AP-1 and PEA3 in the urokinase 
promoter are required for its stimulation by TNF-oz 
The expression of c-jun/c-fos and c-ets, which are 
involved in transcriptional control via AP-1 and PEA3 
binding sites respectively [22,23], is induced by TNF-a 
[24-26]. With this in mind, we undertook experiments o
determine if target sequences for AP-1 and PEA3 residing 
between -2109 and - 1870 were required for the stimula- 
tion of the urokinase promoter by TNF-a. Mutations of the 
PEA3 (mutant A) and AP-1 (mutant B) motifs at - 1973 
and -1967 reduced the basal level of the urokinase 
promoter in UM-SCC-1 cells and abrogated the inductive 
effect of TNF-a (Fig. 3). Additionally, a sequence ( - 1947 
to -1941) in the promoter further downstream was also 
critical for increased urokinase promoter activity. Thus, 
:t+++tt+++± 
+ +-  
nuclear extract 
wt AP-1 competitor 
mutated AP-1 competitor 
jun Ab 
Control 
Fig. 4. TNF-ot stimulates AP-l-binding activity in UM-SCC-1 cells. UM-SCC-1 nuclear extract from TNF-ot-treated, or untreated cells, was preincubated 
at 4 ° C for 30 min with, or without 2 p,g of a jun antibody (jun Ab) and then for 20 min with 5 fmol (2 × 104 cpm) of an end-labelled (32p-ATP) 30-mer 
oligonucleotide spanning the AP-1 binding site at - 1967 of the urokinase promoter. Parallel incubations included a 100-fold excess of an unlabelled 
oligonucleotide which was either identical to the radioactive probe (wt AP-1 competitor) or which had been point mutated within the AP-1 site (mutated 
AP-1 competitor). After this time, the reaction mixture was electrophoresed in a 6% polyacrylamide g l using a 0.5 X TBE running buffer. The experiment 
was carried out 3 times. 
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mutation of this region (mutant F) also led to a reduction 
in basal activity of the promoter as well as an abolition of 
the TNF-c~-induced response. 
3.4. TNF-ot stimulates AP-l-binding activity in UM-SCC-1 
cells 
Since the stimulation of the urokinase promoter by 
TNF-c~ could be abrogated by a point mutation of the 
AP-1 binding site at -1967,  we speculated that an in- 
crease in AP-l-binding activity brought about by TNF-ce 
could underscore the increased expression of the protease 
in response to this cytokine. To address this, nuclear 
extract from TNF-a-treated and untreated cells was incu- 
bated with an end-labelled radioactive oligonucleotide 
probe (Fig. 4) containing the AP-1 sequence (at -1967)  
present in the urokinase promoter. The reaction mixture 
was subsequently subjected to gel electrophoresis. An 
oligonucleotide-containing complex (solid arrow) which 
could be competed out with an excess of unlabelled oligo- 
nucleotide was observed with nuclear extract from un- 
treated UM-SCC-1 cells. The intensity of this band was 
greatly enhanced with nuclear extracts generated from 
TNF-a-stimulated cells. The inability of an oligonucleotide 
sequence, which was mutated in the AP-l-binding region 
of the probe, to compete with the radioactive oligonucleo- 
tide for the binding of the nuclear factor(s) indicated the 
specificity of this association. A supershifted complex 
(open arrow) was also evident when nuclear extract was 
pre-incubated with an antibody which recognizes jun- 
family members. The intensity of the super-shifted band 
was substantially higher with nuclear extracts from TNF- 
c~-stimulated UM-SCC-1 cells. These data suggested that 
TNF-a increases the amount of AP-l-binding activity in 
UM-SCC-1 cells. 
3.5. TNF-a stimulates a reporter construct driven by AP-1 
tandem repeats 
To determine if the increase in AP-l-binding activity 
brought about by TNF-a treatment could stimulate pro- 
moter activity, UM-SCC-I cells were transiently trans- 
fected with a CAT reporter driven by either a thymidine 
kinase minimal promoter (PBL CAT) or 3 tandem AP-1 
repeats upstream of the minimal promoter (3 X AP-1 PBL 
CAT) [21]. The cells were subsequently treated with TNF-c~ 
and assayed for CAT activity (Fig. 5). A weak activation 
of the minimal promoter, which was not changed by 
TNF-c~ treatment, was observed with UM-SCC-1 cells 
transiently transfected with the thymidine kinase minimal 
promoter CAT construct (PBL CAT). In contrast, cultiva- 
tion of the UM-SCC-I cells transfected with the AP-1- 
60 
~ 50 
<40 
O 
"~ 30 
2o 
• = 10 r..) 
0 
- + - + ffNF- ) 
PBL CAT 3X AP-1 PBL CAT 
I I 
D c0ntrol 
~ +TNF-a (100 
II! 
Iii 
PBL CAT 3X AP-1 PBL CAT 
Fig. 5. TNF-ot stimulates a tk-CAT reporter driven by AP-I tandem repeats UM-SCC-1 cells were transiently transfected with a CAT reporter driven by 3 
tandem repeats of an AP-1 binding site upstream ofa thymidine kinase minimal promoter (3× AP-1 PBL CAT) or the CAT construct lacking the AP-1 
sequence (PBL CAT). After 12 h, the cells were treated with (+), or without (-), 100 ng/ml TNF-a for 48 h. The cells were harvested and assayed for 
CAT activity as described in the legend to Fig. 2. The conversion of [14C]chloramphenicol wasquantified using a 603 Betascope. The data are 
representative of 2 separate experiments. 
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driven promoter (3 × AP-1 PBLCAT) with TNF-a ele- 
vated CAT activity more than 4-fold over that achieved 
with untreated cells. These data suggest hat the induction 
of AP-l-binding activity by TNF-a apparent in the mobil- 
ity shift assays is sufficient o stimulate an AP-l-contain- 
ing minimal promoter. 
4. Discussion 
The stimulation of urokinase production in endothelial 
cells and malignant cell types by TNF-a has been reported 
previously [6,7,27] and is considered to be a critical factor 
in tissue remodeling as evident in tumor cell invasion and 
angiogenesis. The elevated production of the protease by 
this cytokine in pulmonary epithelial cells has been as- 
cribed to increased transcriptional ctivity as shown by 
nuclear un on experiments [28]. We have extended these 
findings, herein, by showing that the induction of uroki- 
nase expression by TNF-c~ in a squamous cell carcinoma 
cell line is mediated, at least in part, by binding sites for 
AP-1 ( -  1967) and PEA3 ( -  1973) upstream of the uroki- 
nase transcriptional start site. 
The AP-1 transcription complex is comprised of bet- 
erodimers of jun and fos family members and to a lesser 
extent homodimers of jun [29,30]. Binding of AP-1 to its 
cognate sequence leads to altered transcriptional ctivity. 
In fact, several observations suggest that modulation of the 
activity and/or amount of AP-1 is responsible for the 
increased level of urokinase mRNA/protein evident in 
TNF-a-stimulated UM-SCC-1 cells. Thus, the binding of 
the AP-1 complex to its recognition sequence at -1967 
has been shown to be critical for the inductive effect of 
EGF and phorbol ester on urokinase xpression [18,20]. 
Additionally, the induction of c-jun and c-fos expression 
by TNF-ce leads to altered expression of AP-l-containing 
genes including the chemoattractant JE, elastin and colla- 
genase [31-33]. Indeed, in an earlier investigation, differ- 
ential screening of cDNA libraries had revealed the c-jun 
transcription factor to be an overexpressed gene in TNF- 
a-stimulated human umbilical endothelial cells [25]. These 
observations were consistent with our gel retardation ex- 
periments which showed that the AP-1 activity in UM- 
SCC-1 cells, which was increased by TNF-a treatment, 
contained a jun protein(s). Thus, put together, these find- 
ings suggest that the effect of TNF-a on urokinase xpres- 
sion is mediated, at least in part, via the modulation of the 
amount and/or expression of AP-1. 
Our study demonstrates that a PEA3 binding site 
(located at - 1973) is also required for the stimulation of 
urokinase xpression by TNF-a. The PEA3 binding site 
recognizes multiple members of the c-ets family of tran- 
scription factors [23] and is required for the basal expres- 
sion of the plasminogen activator in a number of cell lines 
[20]. Further, this sequence participates in the induction of 
urokinase xpression in EGF-and phorbol ester-stimulated 
murine keratinocytes [18,20]. Presumably, TNF-a in- 
creases the amount and/or activity of a PEA3-binding 
protein, this leading to increased urokinase promoter activ- 
ity. This contention is supported by reports from other 
laboratories. Firstly, the amount of c-ets mRNA in conflu- 
ent human umbilical vein endothelial cells was transiently 
increased by this cytokine [34]. Secondly, and perhaps 
more importantly, the ability of TNF-a to modulate the 
expression of member(s) of the c-ets family appeared to be 
critical for the repression of thrombomodulin expression i
TNF-a-stimulated endothelial cells [26]. 
While the induction of urokinase xpression by TNF-a 
in UM-SCC-1 cells requires transcription factor binding 
sites for PEA3 and AP-1, the early events in this signal 
transduction pathway remain to be elucidated. Since the 
transcription factors, which bind to these promoter sites, 
have been characterized aseffectors of protein kinase C, it 
is likely that this signal transduction pathway is involved 
in the TNF-a stimulation of urokinase xpression. Indeed, 
other investigators have demonstrated the requirement for 
the protein kinase C pathway in the actions of TNF-a. 
Thus, Hanazawa et al. [32] demonstrated that the induction 
of the monocyte chemoattractant JE by TNF-a required 
PKC since this stimulation could be abrogated by a prior 
desensitization f the PKC pathway. Likewise, the induc- 
tion of urokinase xpression i  endothelial cells by TNF-a 
was blocked with staurosporine and calphostin-C [14], thus 
testifying to the involvement of protein kinase C. 
Although the transcriptional requirements for TNF-a 
and phorbol ester stimulation of urokinase xpression are 
similar, there are distinct differences which are worth 
comment. Most prominent is the role of a region of the 
urokinase promoter which contains the nuclear inhibitor 
protein (NIP) binding motif, previously characterized asa 
regulatory component of the human interleukin-3 and 
stromelysin promoters [35,36]. Mutation of this sequence 
substantially reduced the stimulation of the urokinase pro- 
moter by phorbol ester [18]. In contrast, mutation of this 
transcription factor binding site (mutant I), did not attenu- 
ate the induction of urokinase promoter activity by TNF-a 
in our cells. In fact, the stimulation appeared to be aug- 
mented by this mutation. One possible explanation is that 
this sequence may contain a repressor motif for TNF-a 
stimulation which, upon mutation, superinduces the TNF-a 
response. This key difference in transcriptional require- 
ments for TNF-a and phorbol ester stimulation may be 
explained in either of two ways. Firstly, it is possible that 
the stimulation of urokinase expression by TNF-a in 
UM-SCC-1 cells involves both protein kinase C-dependent 
and -independent pathways. Alternatively, it may be that 
the protein kinase C pathways are distinct in the separate 
cell lines used in the two studies. 
In summary, we have demonstrated that the stimulation 
of urokinase xpression by TNF-a in a squamous carci- 
noma cell line is mediated, at least in part, by members of 
the PEA3 and AP-1 transcription factor families. 
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